Page last updated: 2024-12-08
tulipalin b
Description
tulipalin B: RN given refers to (S)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
tulipalin B : A member of the class of butan-4-olides that is 3-methylidenebutan-4-olide carrying an additional hydroxy substituent at position 4 (the 4R-enantiomer) [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 162351 |
SCHEMBL ID | 4922801 |
MeSH ID | M0140230 |
Synonyms (15)
Synonym |
tulipalin b |
38965-80-9 |
(4s)-4-hydroxy-3-methylideneoxolan-2-one |
4-hydroxy-3-methylideneoxolan-2-one |
15vwd3k2a9 , |
beta-hydroxy-alpha-methylene-gamma-butyrolactone |
2(3h)-furanone, dihydro-4-hydroxy-3-methylene-, (s)- |
unii-15vwd3k2a9 |
singleex tulipalin |
2(3h)-furanone, dihydro-4-hydroxy-3-methylene-, (4s)- |
tulipalin b [inci] |
(s)-(-)-tulipalin b |
SCHEMBL4922801 |
C21187 |
DTXSID30959815 |
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 2 (25.00) | 18.7374 |
1990's | 2 (25.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.66 (24.57) | Research Supply Index | 2.20 (2.92) | Research Growth Index | 4.86 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |